Home > Healthcare > Pharmaceuticals > Finished Drug Form > Hyperlipidemia Drugs Market

Hyperlipidemia Drugs Market Size

Report ID: GMI10320
Published Date: Jul 2024
Report Format: PDF

Download Free Sample

Hyperlipidemia Drugs Market Size

Hyperlipidemia Drugs Market size was valued at around USD 21.6 billion in 2023 and is estimated to grow at 3.2% CAGR from 2024 to 2032. Hyperlipidemia drugs are medications used to treat hyperlipidemia, a condition characterized by abnormally high levels of lipid and fats in the blood, such as cholesterol and triglycerides. These drugs aim to lower lipid levels to reduce the risk of cardiovascular diseases, including heart attack and stroke.

To get key market trends

Download Free Sample

The rising prevalence of cardiovascular diseases is a significant driving factor for the market. For instance, according to a study published by National Library of Medicine in January 2024, coronary artery disease (CAD) accounts for approximately 6,10,000 deaths annually (estimated 1 in 4 deaths) and is the leading cause of mortality in the U.S. Also, it is third leading cause of mortality worldwide and is associated with 17.8 million deaths annually. This underscores the critical need for effective hyperlipidemia drugs to manage lipid levels and reduce the risk of cardiovascular events.

Hyperlipidemia Drugs Market Report Attributes
Report Attribute	Details
Base Year:	2023
Hyperlipidemia Drugs Market Size in 2023:	USD 21.6 Billion
Forecast Period:	2024 - 2032
Forecast Period 2024 - 2032 CAGR:	3.2%
2032 Value Projection:	USD 28.5 Billion
Historical Data for:	2021 - 2023
No. of Pages:	210
Tables, Charts & Figures:	284
Segments covered:	Type, Drug Class, Route of Administration, Distribution Channel, and Region
Growth Drivers:	Rising prevalence of hyperlipidemia Advancements in drug development Growing incidence of cardiovascular diseases Rising geriatric population
Pitfalls & Challenges:	High cost of advanced therapies Side effects and adverse reactions

Learn more about the key segments shaping this market

Download Free Sample

Furthermore, rising prevalence of hyperlipidemia, advancements in drug development, and rising geriatric population are also among the key factors promoting the growth of the market.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Hyperlipidemia drugs industry size was valued at around USD 21.6 billion in 2023 and is estimated to record 3.2% CAGR from 2024 to 2032, owing to the rising prevalence of cardiovascular diseases, advancements in drug development, and rising geriatric population.

The acquired segment of the market is predicted to reach USD 18.5 billion by 2032, on account of the increasing incidence of lifestyle-related disorders as well as the high prevalence of acquired hyperlipidemia, favoring the availability of multiple drugs, including statins, fibrates, bile acid sequestrants, and PCSK9 inhibitors.

The U.S. hyperlipidemia drugs market is projected to reach USD 10.5 billion by 2032, as the region boasts a robust pharmaceutical sector characterized by extensive investment in R&D, fostering continuous innovation in hyperlipidemia drugs, leading to the discovery of novel therapies, improved formulations, and enhanced treatment strategies.

AstraZeneca PLC, Amgen Inc., Alnylam Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Dr. Reddy’s Laboratories Limited, Eli Lilly and Company, and F. Hoffmann-La Roche Ltd. among others.